



# Superficial and Deep calcium are more prevalent in Peripheral Vasculature<sup>1</sup>




# IVL offers Multiple Applications in Peripheral Arterial Calcification




# Complex Real-world Patients and Lesions


Largest prospective 'real-world' evidence for the treatment of complex, heavily calcified PAD



## Challenges Associated with Calcium



Access for Large-Bore Devices



Perforations



Dissections



Vessel Recoil



Embolization



Stent Crush

## Disrupt PAD Clinical Program

> 40 Peer-Reviewed Publications


> 1600 Patients

	Disrupt PAD I	Disrupt PAD II	Disrupt BTK	Disrupt PAD III RCT	Disrupt PAD III OS	Disrupt PAD+	Disrupt BTK II
Study design	Single arm, safety & performance	Single arm, safety & effectiveness	Single arm, pilot	Single arm, RCT, safety & effectiveness	Single arm, observational study	Single arm, safety & performance	Single arm, safety & performance
Vessel beds	SFA, Pop	SFA, Pop	BTK	SFA, Pop	Iliac, CFA SFA, Pop BTK	Iliac, CFA SFA, Pop BTK	BTK
#of patients/sites	35/3	60/8	20/3	306/45	1373/30	37/8	250/42

## Real-world Outcomes Consistent with Randomized Trial

IVL Safely and Effectively Modifies Calcium Across Multiple Vessel Beds

	DISRUPT PAD III RCT <sup>1</sup>	DISRUPT PAD III OS <sup>1</sup>
N	153	1367
Vessels	SFA/Pop	Iliac, CFA, SFA /Pop, Infrapop
Dissection (Type D-F)	0%	0.7%
Perforation	0%	0.2%
Embolization	0%	0%
Slow Flow/No Reflow	0%	0%
Abrupt Closure	0%	0%
Thrombus	0%	0%



Exceptional SAFETY Profile

Proven EFFECTIVE Calcium Modification




Ref. 1: Soor et al, Peripheral vascular disease who gets it and why? Pathology 2008

†PARC Definition. Armstrong E, VIVA Late Breaking Clinical Trial 2022, SPL-67519 Rev. B - DISRUPT PAD III Observational Study-1373 In-Service. © 2022 Shockwave Medical Inc. All rights reserved.

# Predictable Outcomes In Challenging Situations

Predictably consistent results across complex patients, challenging lesions & vessel beds

## Majority of stenosis reduction from IVL treatment



# SHOCKWAVE | M<sup>5+</sup>

## CATHETER SPECS

Catalog Number	Balloon Diameter (mm)	Balloon Length (mm)	Sheath Compatibility	Catheter Working Length	Pulses/Cycle	Cycles	Pulses (Max)	Balloon Crossing Profile (in)
M5PIVL 3560	3.5	60	6F	135	30	10	300	.054
M5PIVL 4060	4.0	60	6F	135	30	10	300	.054
M5PIVL 4560	4.5	60	6F	135	30	10	300	.057
M5PIVL 5060	5.0	60	6F	135	30	10	300	.061
M5PIVL 5560	5.5	60	6F	135	30	10	300	.062
M5PIVL 6060	6.0	60	6F	135	30	10	300	.065
M5PIVL 6560	6.5	60	6F	135	30	10	300	.066
M5PIVL 7060	7.0	60	6F	135	30	10	300	.068
M5PIVL 8060	8.0	60	7F	135	30	10	300	.074

\*6F Compatible with Terumo Pinnacle® Destination® Guiding Sheath and Cook Flexor® Ansel Guiding Sheath. Referenced trademarks are trademarks of their respective owners or holders.

# SHOCKWAVE | S<sup>4</sup>

## CATHETER SPECS

Catalog Number	Diameter (mm)	Length (mm)	Sheath Compatibility	Working Length	Pulses/Cycle	Cycles	Pulses (Max)	Crossing Profile (in)
S4IVL 2540	2.5	40	5F	135	20	8	160	.048
S4IVL 3040	3.0	40	5F	135	20	8	160	.048
S4IVL 3540	3.5	40	5F	135	20	8	160	.048
S4IVL 4040	4.0	40	5F	135	20	8	160	.050

**translumina**  
LIMITLESS POSSIBILITIES

Discover how you can treat calcium more effectively with the Peripheral Intravascular Lithotripsy (IVL) System. For more information Visit [shockwavemedical.com](http://shockwavemedical.com)

TransAcademy



Playstore



Appstore

**translumina**  
LIMITLESS POSSIBILITIES

## Peripheral

# SHOCKWAVE | IVL



PREDICTABLY SAFE | DISTINCTIVELY INTUITIVE | CONSISTENTLY EFFECTIVE

1: Tepe et al. J Am Coll Cardiol Intv 2021. 2: Armstrong E. VIVA Late Breaking Clinical Trial 2022. SPL-67519 Rev. B-DISRUPT PAD III Observational Study-1373 In-Service. © 2022 Shockwave Medical Inc. All rights reserved. Armstrong E. Late Breaking Clinical Trial and Shockwave-Sponsored Symposium, VIVA 2022